At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
At a recent dinner symposium, an expert from Belgium presented on the management of allergic rhinitis, with a particular focus on the use of oral H1-antihistamines and intranasal glucocorticosteroids.
In conjunction with the launch of BETADINE® Daily Feminine Wash Foam & Liquid, two eminent local speakers, Datuk Dr Nor Ashikin Mokhtar and Dr Liew Fah Onn spoke on the importance of feminine hygiene and holistic approaches for managing vaginal infections, respectively.
Scar treatment has significantly evolved over the past few decades. New treatments are constantly being developed to manage pathologic scars and make surgical scars less noticeable. At a recent dinner symposium, Professor Dr Kim Yong Oock shared the latest information about Asian scar management, with particular interest in the use of silicone gel therapy. Below are highlights of his talk.
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Angiotensin-converting enzyme inhibitors (ACEIs) vs angiotensin receptor blockers (ARBs) for hypertension: Does it matter?
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)